AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 262 min read$INSM

Lewis William sold $2.2M of INSM

Lewis William (Chair and CEO) sold 21,398 shares of INSMED Inc (INSM) at an average of $103.32 ($102.34–$106.27, $2.21M total) across 5 trades on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lewis William
Published Jun 26, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INSM
Neutral
high confidence
Mentioned
$INSM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The newest disclosed fact is the $2.21M open-market sale executed across five trades on 2026-06-25, under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may note the insider selling as a sentiment datapoint, but the 10b5-1 structure and lack of company-specific news limit trading impact.

03

What to watch

The article does not disclose any concurrent company-specific catalyst (earnings, trial readout, financing, or regulatory event), so traders should avoid over-weighting the sale versus fundamentals.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-26 after trades on 2026-06-25

Background

This is an SEC Form 4 insider transaction disclosure for INSMED Inc, reported by Lewis William (Chair and CEO).

Company-level read

Ticker impact

$INSMNeutralHigh confidence
Context

INSMED CEO and Chair Lewis William sold about 21,398 shares in open-market trades totaling $2.21M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces signaling value versus discretionary sales.

Market effects

Sector

No sector-wide read-through is provided beyond routine insider activity at a single biotech issuer.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal views on near-term risk, especially if other insiders also sell.

Key entities

  • issuer
    INSMED Inc

    US-listed company whose CEO/Chair insider sale is disclosed via Form 4.

  • insider
    Lewis William

    Chair and CEO who sold shares totaling $2.21M under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INSM insider trading history →

Related articles

SEP 28
$INSMMedAI 8/10

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Insmed (INSM) announced the FDA granted priority review for its ARIKAYCE lung drug, setting a January 2027 decision date. The application seeks full approval for broader use in treating MAC lung disease. Clinical trial results showed significant improvements in respiratory symptoms and bacterial conversion rates. Success could expand the patient pool and increase revenue, but regulatory, tolerability, and commercialization risks remain.

insidermonkey.com2 min
SEP 22
$INSMHighAI 8/10

FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

Insmed (INSM) announced the FDA accepted its filing for Arikayce's label expansion to treat newly diagnosed MAC lung disease, with a decision expected by Jan. 28, 2027. The filing is supported by positive phase IIIb ENCORE study results. Arikayce sales grew 7% YoY to $214.4M in H1 2026, with full-year sales projected at $450M-$470M. The expansion could significantly increase Arikayce's market potential, according to the company.

zacks.com2 min
SEP 21
HighAI 8/10

Why is Insmed stock climbing today?

Insmed stock rose 2.0% in pre-market trading after the FDA accepted and granted Priority Review to its sNDA for ARIKAYCE, targeting a decision by January 28, 2027. The application seeks full approval for the drug, backed by Phase 3b ENCORE study results. Full approval would expand ARIKAYCE's use to newly diagnosed patients and those with recurrent infections. Insmed also plans to engage Japan's pharmaceutical regulator in Q4 2026 for potential label expansion.

investing.com2 min
SEP 21
$INSMHighAI 8/10

Insmed stock rises on FDA priority review for Arikayce

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.

investing.com1 min